NVS - Why Is European Pharma Giant Novartis Stock Trading Lower Today? | Benzinga
Wednesday, Novartis AG (NYSE:NVS) reported fourth-quarter 2023 net sales of $11.42 billion, up 8% (up 10% at constant currency, cc) driven by volume growth of 13 percentage points. The sales fell short of the consensus of $11.76 billion.
Generic competition had a negative impact of 3 percentage points, and pricing had no impact.
Sales growth was mainly driven by a continued strong performance from Entresto (+26% cc), Kisqali (+76% cc), Kesimpta (+73% cc), Cosentyx (+21% cc), and Pluvicto (+53% cc).
Also Read: Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA ...